Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates.
The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology.
Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression.
"Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev.
Key findings presented:
Detection of ctDNA following CRT was independently prognostic of patient outcomes.
Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT.
Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans.
High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death.
"We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients."
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
Not affiliated with or endorsed by ASCO.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603114064/en/
Contacts
Investors: Caroline Cornerinvestors@personalis.com 415-202-5678
Media Contact pr@personalis.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Writer Named a Gartner® Cool Vendor for AI Agent Development
SAN FRANCISCO--(BUSINESS WIRE)-- Writer, the leader in enterprise generative AI, today announced that it has been named a Cool Vendor in the inaugural 2025 Gartner® Cool Vendors™report for AI Agent Development. Over the last 5 years, Writer has pioneered the enterprise AI category with the world's only enterprise-focused AI research lab and now leads the industry with an end-to-end approach to agentic AI. Today, Writer's platform enables IT and business teams from hundreds of leading enterprises to collaboratively build and scale AI agents that streamline workflows across departments. According to Gartner, 'by 2029, over 60% of enterprises will adopt AI agent development platforms to automate complex workflows previously requiring human coordination.' The report states, 'Demand for AI agent development is increasing as organizations seek hyperefficiency. Software engineering leaders will find the vendors in this report valuable for addressing the growing demand from business and technology stakeholders to develop agents that will help them deliver business value faster.' Based on Writer's understanding, Cool Vendors were selected for their ability to provide both the foundational tools to harness the potential of AI agents, as well as innovative value-add functionality. Writer's primary takeaway from the report is that enterprises must invest in vendors that can offer scalability, interoperability, and stability, in addition to performance and security, to maximize long term value. 'Being named a Gartner Cool Vendor in AI Agent Development is an important recognition of Writer's platform,' said May Habib, CEO and Co-Founder of Writer. 'In a noisy market full of overpromises, Writer delivers what enterprises actually need: agentic systems that are accurate, governed, and built to scale. Our platform gives IT and business teams one place to build, activate, and supervise AI agents — grounded in business context, powered by our enterprise-grade LLMs, and built for real ROI.' Writer has recently released new product and tech innovations, including: Palmyra X5: Writer's latest foundation model, topping benchmarks for speed, cost efficiency, and large context performance. AI HQ: Writer's centralized hub to build, activate, and supervise AI agents across the enterprise. Includes a library of 100+ ready-to-use AI agents across industries including finance, healthcare, retail, and technology. Together, Palmyra X5 and AI HQ give enterprises unmatched power to deploy real-world AI agents that support use cases like market intelligence, financial reporting, legal analysis, medical record synthesis, and customer experience optimization. Hundreds of leading enterprises – including Intuit, Kenvue, Marriott, Qualcomm, Uber, Vanguard, and more – use Writer to reinvent business processes with AI at the center. Readers can access a complimentary copy of the report here. Disclaimer Gartner, Cool Vendors for AI Agent Development, Adrian Leow, Jim Scheibmeir, Nitish Tyagi, Manjunath Bhat, 27 May 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Writer Writer is where the world's leading enterprises orchestrate AI-powered work. With Writer's end-to-end platform, teams can build, activate, and supervise AI agents that are grounded in their company's data and fueled by Writer's enterprise-grade LLMs. From faster product launches to deeper financial research to better clinical trials, companies are quickly transforming their most important business processes for the AI era in partnership with Writer. Founded in 2020, Writer delivers unmatched ROI for hundreds of customers like Accenture, Intuit, Marriott, Uber, and Vanguard and is backed by investors including Premji Invest, Radical Ventures, ICONIQ Growth, Insight Partners, Balderton, B Capital, Salesforce Ventures, Adobe Ventures, Citi Ventures, IBM Ventures, and others. Learn more at
Business Wire
16 minutes ago
- Business Wire
Press Release of June 5, 2025, Relating to the Availability of the Response Document Prepared by the Company Verallia in the Context of the Tender Offer for the Shares of the Company Verallia Initiated by Kaon V
PARIS--(BUSINESS WIRE)--Regulatory News: This press release has been prepared by Verallia (Paris:VRLA) and issued on June 5, 2025, in accordance with the provisions of article 231-26 of the General Regulation of the French Autorité des marches financiers (the ' AMF '). Pursuant to article L. 621-8 of the French Monetary and Financial Code and article 231-26 of the AMF General Regulation, the AMF has, pursuant to its clearance decision dated June 5, 2025, regarding the tender offer for Verallia shares (the ' Offer '), granted visa no. 25-197 to the response document prepared by Verallia (' Response Document '). The Response Document approved by the AMF on June 5, 2025, is available on the websites of the AMF ( and Verallia ( and may be viewed free of charge at the registered office of Verallia (31 Place des Corolles, Tour Carpe Diem, Esplanade Nord, 92400 Courbevoie). Prior to the opening of the Offer, the AMF and Euronext Paris will publish, respectively, a notice of opening and timetable and a notice announcing the terms and timetable of the Offer. In accordance with article 231-28 of the AMF's General Regulations, the document on other information relating to the legal, financial and accounting characteristics of Verallia will be filed with the AMF and made available to the public, under the same terms and conditions, no later than the day before the opening of the tender offer. A press release will be issued, no later than the day before the opening of the tender offer, to inform the public of the procedures for making this document available. Disclaimer This press release has been prepared for information purposes only. It does not constitute an offer to the public and should not be considered as constituting any form of solicitation for the purchase or sale of financial securities. The distribution of this press release, the Offer and its acceptance may be subject to specific regulations or restrictions in certain countries. The Offer is not addressed to persons subject to such restrictions, either directly or indirectly, and is not intended to be accepted from any country where the Offer would be subject to such restrictions. This press release is not intended for distribution in such countries. Accordingly, persons in possession of this press release are required to inform themselves about and to comply with any local restrictions that may apply. Verallia declines all responsibility for any violation by any person of these restrictions. This press release does not constitute a tender offer and is not intended for distribution in jurisdictions where the offer would not be permitted. This document is an unofficial English-language translation of the press release relating to the filing of the response document (note en réponse) which was published by Verallia on 5 June, 2025. In the event of any discrepancies between this unofficial English-language translation and the official French press release, the official French press release shall prevail. Expand
Business Wire
17 minutes ago
- Business Wire
HireRight Releases 2025 Global Benchmark Report
NASHVILLE, Tenn.--(BUSINESS WIRE)--HireRight, a leading provider of global background screening services and workforce management solutions, today announced the release of its 2025 Global Benchmark Report. This year's comprehensive report identifies regional and global trends in background screening, talent acquisition, and workforce management, based on the survey responses of more than 1,000 human resource, risk, and talent acquisition professionals worldwide, collected between Feb. 11 and March 9, 2025. Among this year's survey findings, accuracy of results held its position as the most frequently cited priority for employers when choosing their employment screening provider. Among this year's survey findings, accuracy of results held its position as the most frequently cited priority for employers when choosing their employment screening provider. Compared with our 2023 and 2024 survey findings, fewer respondents said that cost and speed are major considerations this year, suggesting that many businesses are willing to spend a little more time and/or money on their background checks if it improves the accuracy of their findings. Other survey results shared in HireRight's 2025 Global Benchmark Report include: More than three-quarters of businesses have found candidate discrepancies during the screening process in the last 12 months. Undisclosed criminal convictions and education and employment discrepancies were the most common types of candidate inconsistency identified. Many businesses are still not conducting identity checks despite rising levels of ID fraud. Worryingly, one in six respondents said their business has experienced ID fraud as part of their hiring process, and an additional three out of 10 were unsure. Candidates dropping out if remote working wasn't offered was the top recruitment challenge in 2024. The next most common challenges last year were positions remaining unfilled for three to six months (North America and APAC) and understaffing in HR/recruitment teams (EMEA). Most companies are unsure how to respond to candidates using generative artificial intelligence (AI) in the hiring process. Seven out of 10 respondents globally said their company was undecided on their views on candidates using generative AI tools to assist with their job applications or resumes; however, of the minority that expressed a view, slightly more saw it as a positive than a negative. Finding qualified job candidates is the most common talent acquisition challenge expected for 2025. Other top concerns include candidates ghosting their potential employers (being non-responsive), fielding multiple job offers at the same time, and not having their pay/benefits expectations met. 'As the economic and hiring landscape continues to shift, the findings in HireRight's 2025 Global Benchmark Report give an insight into current global perspectives on background screening, hiring trends, and the use of new technologies, such as AI, in the recruitment process,' said Euan Menzies, President and CEO at HireRight. 'We are eager to share our survey's findings to help support organizations refine their hiring and retention strategies'. For more information and to download HireRight's 2025 Global Benchmark Report, please visit HireRight is a leading global provider of technology-driven workforce risk management and compliance solutions. We provide comprehensive background screening, verification, identification, monitoring, and drug and health screening services for approximately 34,000 customers around the globe. We offer our services via a global platform that tightly integrates into our customers' human capital management systems enabling highly effective and efficient workflows for workforce hiring, onboarding, and monitoring. In 2024, we screened more than 60 million job applicants, employees, and contractors for our customers and processed more than 120 million screens. For more information, visit
